{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T20:59:34Z","timestamp":1784581174106,"version":"3.55.0"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100019984","name":"Yan'an Science and Technology Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019984","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.critrevonc.2026.105292","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:18:09Z","timestamp":1774052289000},"page":"105292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Immunotherapy and ferroptosis regulation in thyroid cancer: Novel strategies and future perspectives"],"prefix":"10.1016","volume":"222","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1389-7402","authenticated-orcid":false,"given":"SiYu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"QiangFang","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YanJie","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"QianQian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LeYi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WenHan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MingZheng","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HaoXuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LiLi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XiaoLong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105292_bib1","article-title":"Thyroid cancer","author":"Boucai","year":"2024","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105292_bib2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13046-025-03593-3","article-title":"Inducing ferroptosis to improve cancer therapy: a promising tool for enhancing immunotherapy","volume":"45","author":"Caforio","year":"2025","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105292_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1119369","article-title":"Ferroptosis and tumor immunotherapy: a promising combination therapy for tumors","volume":"13","author":"Cai","year":"2023","journal-title":"Front Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105292_bib4","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12943-022-01704-8","article-title":"m(6)A methylation: a process reshaping the tumour immune microenvironment and regulating immune evasion","volume":"22","author":"Cao","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105292_bib5","article-title":"Ferroptosis: a new strategy for cancer therapy","volume":"12","author":"Chen","year":"2022","journal-title":"Front Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105292_bib6","doi-asserted-by":"crossref","first-page":"16500","DOI":"10.18632\/aging.203172","article-title":"Circular RNA circKIF4A facilitates the malignant progression and suppresses ferroptosis by sponging miR-1231 and upregulating GPX4 in papillary thyroid cancer","volume":"13","author":"Chen","year":"2021","journal-title":"Aging (Albany NY)"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105292_bib7","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.7150\/thno.72594","article-title":"Antibody-based drug delivery systems for cancer therapy: mechanisms, challenges, and prospects","volume":"12","author":"Chen","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.critrevonc.2026.105292_bib8","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/6896790","article-title":"Curcumin induces ferroptosis in follicular thyroid cancer by upregulating HO-1 expression","volume":"2023","author":"Chen","year":"2023","journal-title":"Oxid. Med Cell Longev."},{"key":"10.1016\/j.critrevonc.2026.105292_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116971","article-title":"Ferroptosis in thyroid cancer: potential mechanisms, effective therapeutic targets and predictive biomarker","volume":"177","author":"Chen","year":"2024","journal-title":"Biomed. & Pharmacother."},{"key":"10.1016\/j.critrevonc.2026.105292_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116971","article-title":"Ferroptosis in thyroid cancer: potential mechanisms, effective therapeutic targets and predictive biomarker","volume":"177","author":"Chen","year":"2024","journal-title":"Biomed. & Pharmacother."},{"key":"10.1016\/j.critrevonc.2026.105292_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122386","article-title":"Biomimetic inducer enabled dual ferroptosis of tumor and M2-type macrophages for enhanced tumor immunotherapy","volume":"303","author":"Chen","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.critrevonc.2026.105292_bib12","article-title":"Keap1-Nrf2 pathway: a key mechanism in the occurrence and development of cancer","volume":"14","author":"Chen","year":"2024","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2026.105292_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.34934","article-title":"The engineered exosomes targeting ferroptosis: a novel approach to reverse immune checkpoint inhibitors resistance","author":"Chen","year":"2024","journal-title":"Int. J. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105292_bib14","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.240391","article-title":"Oxidized phospholipid damage signals as modulators of immunity","volume":"15","author":"Choi","year":"2025","journal-title":"Open Biol."},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105292_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15153898","article-title":"Metabolites and ImMune Response in Tumor Microenvironments","volume":"15","author":"Cortellino","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105292_bib16","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1186\/s12967-023-04664-9","article-title":"Anaplastic thyroid cancer cells reduce CD71 levels to increase iron overload tolerance","volume":"21","author":"D'Aprile","year":"2023","journal-title":"J. Transl. Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105292_bib17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12951-024-02297-8","article-title":"The application of nanoparticles-based ferroptosis, pyroptosis and autophagy in cancer immunotherapy","volume":"22","author":"Deng","year":"2024","journal-title":"J. Nanobiotechnology"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105292_bib18","article-title":"Oxidative stress and age-related tumors","volume":"13","author":"Di Carlo","year":"2024","journal-title":"Antioxid. (Basel)"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105292_bib19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12943-024-01999-9","article-title":"Ferroptotic therapy in cancer: benefits, side effects, and risks","volume":"23","author":"Diao","year":"2024","journal-title":"Mol. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105292_bib20","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1089\/thy.2020.0322","article-title":"Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma","volume":"31","author":"Dierks","year":"2021","journal-title":"Thyroid"},{"key":"10.1016\/j.critrevonc.2026.105292_bib21","doi-asserted-by":"crossref","DOI":"10.34133\/bmr.0214","article-title":"Dual-active nanoimmunomodulators for the synergistic enhancement of the antitumor efficacy of photodynamic immunotherapy","volume":"29","author":"Dong","year":"2025","journal-title":"Biomater. Res"},{"key":"10.1016\/j.critrevonc.2026.105292_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202111784","article-title":"A \u201cclosed-loop\u201d therapeutic strategy based on mutually reinforced ferroptosis and immunotherapy","author":"Du","year":"2022","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.critrevonc.2026.105292_bib23","article-title":"defence of ferroptosis","author":"Francesca","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2026.105292_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2024.117912","article-title":"Anti-papillary thyroid carcinoma effects of Dioscorea bulbifera L. through ferroptosis and the PI3K\/AKT pathway based on network pharmacology and experimental validation","volume":"326","author":"Gao","year":"2024","journal-title":"J. Ethnopharmacol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105292_bib25","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1007\/s12672-024-01573-1","article-title":"Current advances on the role of ferroptosis in tumor immune evasion","volume":"15","author":"Gao","year":"2024","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105292_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122442","article-title":"Boosting the synergism between cancer ferroptosis and immunotherapy via targeted stimuli-responsive liposomes","volume":"305","author":"Gao","year":"2024","journal-title":"Biomaterials"},{"key":"10.1016\/j.critrevonc.2026.105292_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.cytogfr.2025.06.007","article-title":"Ferroptosis in immune cells: implications for tumor immunity and cancer therapy","author":"Gao","year":"2025","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.critrevonc.2026.105292_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116324","article-title":"Targeting Nrf2 to treat thyroid cancer","volume":"173","author":"Gong","year":"2024","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105292_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1137107","article-title":"Deciphering the potential roles of ferroptosis in regulating tumor immunity and tumor immunotherapy","volume":"14","author":"Gu","year":"2023","journal-title":"Front Immunol."},{"key":"10.1016\/j.critrevonc.2026.105292_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1372553","article-title":"Advances in targeted therapy and biomarker research in thyroid cancer","volume":"15","author":"Guo","year":"2024","journal-title":"Front Endocrinol. (Lausanne)"},{"key":"10.1016\/j.critrevonc.2026.105292_bib31","article-title":"Avelumab: search for combinations of immune checkpoint inhibition with chemotherapy","author":"Hamilton","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105292_bib32","article-title":"HDAC3: a multifaceted modulator in immunotherapy sensitization","volume":"13","author":"Han","year":"2025","journal-title":"Vaccin. (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105292_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.782646","article-title":"Anti-PD-1 immunotherapy combined with stereotactic body radiation therapy and GM-CSF as salvage therapy in a PD-L1-positive patient with refractory metastatic thyroid h\u00fcrthle cell carcinoma: a case report and literature review","volume":"11","author":"He","year":"2021","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2026.105292_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.878377","article-title":"Fueling cancer vaccines to improve T cell-mediated antitumor immunity","volume":"12","author":"Hernandez","year":"2022","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2026.105292_bib35","article-title":"A pH-responsive PROTAC-based nanosystem triggers tumor-specific ferroptosis to construct in situ tumor vaccines","volume":"31","author":"Huang","year":"2025","journal-title":"Mater. Today Bio"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105292_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14041061","article-title":"Anaplastic thyroid carcinoma: an update","volume":"14","author":"Jannin","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105292_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.857765","article-title":"FTO prevents thyroid cancer progression by SLC7A11 m6A methylation in a ferroptosis-dependent manner","author":"Ji","year":"2022","journal-title":"Front. Endocrinol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105292_bib38","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","article-title":"Ferroptosis: mechanisms, biology and role in disease","volume":"22","author":"Jiang","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105292_bib39","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s00262-025-04133-w","article-title":"GPX4 is a key ferroptosis regulator orchestrating T cells and CAR-T-cells sensitivity to ferroptosis","volume":"74","author":"K\u0142opotowska","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105292_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216119","article-title":"Targeting GPX4 in human cancer: implications of ferroptosis induction for tackling cancer resilience","volume":"559","author":"Lee","year":"2023","journal-title":"Cancer Lett."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105292_bib41","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/cac2.12319","article-title":"PKC\u03b2II-ACSL4 pathway mediating ferroptosis execution and anti-tumor immunity","volume":"42","author":"Lei","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.critrevonc.2026.105292_bib42","article-title":"Advances in PD-1\/PD-L1 pathway inhibitors in the treatment of thyroid cancer: mechanisms and clinical therapeutic perspectives","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105292_bib43","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s11010-022-04541-x","article-title":"ALKBH5 inhibits thyroid cancer progression by promoting ferroptosis through TIAM1-Nrf2\/HO-1 axis","volume":"478","author":"Li","year":"2023","journal-title":"Mol. Cell Biochem"},{"key":"10.1016\/j.critrevonc.2026.105292_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117298","article-title":"Firing up \"cold\" tumors: ferroptosis causes immune activation by improving T cell infiltration","volume":"179","author":"Li","year":"2024","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105292_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmed.2023.05.013","article-title":"FSP1: a key regulator of ferroptosis","author":"Li","year":"2023","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.critrevonc.2026.105292_bib46","article-title":"Nanoparticles synergize ferroptosis and cuproptosis to potentiate cancer immunotherapy","author":"Li","year":"2024","journal-title":"Adv. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105292_bib47","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/s41467-024-45160-y","article-title":"The anti-PD-L1\/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial","volume":"15","author":"Li","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105292_bib48","article-title":"Neferine exerts ferroptosis-inducing effect and antitumor effect on thyroid cancer through Nrf2\/HO-1\/NQO1 inhibition","volume":"2022","author":"Li","year":"2022","journal-title":"J. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105292_bib49","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s13046-025-03520-6","article-title":"Targeting the interplay of cGAS-STING and ferroptosis by nanomedicine in the treatment of cancer","volume":"44","author":"Li","year":"2025","journal-title":"J. Exp. Clin. Cancer Res"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105292_bib50","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/tox.23992","article-title":"Ubiquitin-specific peptidase 10 attenuates the ferroptosis to promote thyroid cancer malignancy by facilitating GPX4 via elevating SIRT6","volume":"39","author":"Lian","year":"2024","journal-title":"Environ. Toxicol."},{"key":"10.1016\/j.critrevonc.2026.105292_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2023.05.003","article-title":"Ferroptosis surveillance independent of GPX4 and differentially regulated by sex hormones","author":"Liang","year":"2023","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105292_bib52","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41420-025-02415-x","article-title":"Ferroptosis: CD8(+)T cells' blade to destroy tumor cells or poison for self-destruction","volume":"11","author":"Liang","year":"2025","journal-title":"Cell Death Discov."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105292_bib53","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ccell.2022.02.003","article-title":"CD8(+) T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4","volume":"40","author":"Liao","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2026.105292_bib54","doi-asserted-by":"crossref","DOI":"10.1590\/1414-431x2024e13679","article-title":"Synergy between isobavachalcone and doxorubicin suppressed the progression of anaplastic thyroid cancer through ferroptosis activation","volume":"57","author":"Lin","year":"2024","journal-title":"Braz. J. Med Biol. Res"},{"key":"10.1016\/j.critrevonc.2026.105292_bib55","article-title":"The crosstalk of CD8+ T cells and ferroptosis in cancer","volume":"14","author":"Lin","year":"2023","journal-title":"Front Immunol."},{"key":"10.1016\/j.critrevonc.2026.105292_bib56","article-title":"Research progress on the cross-regulation between ferroptosis and immunogenic cell death in tumor micro-environment","volume":"15","author":"Liu","year":"2025","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2026.105292_bib57","article-title":"Targeting ferroptosis: a novel insight into thyroid cancer therapy","volume":"16","author":"Liu","year":"2025","journal-title":"Front Endocrinol. (Lausanne)"},{"key":"10.1016\/j.critrevonc.2026.105292_bib58","article-title":"Ferroptosis: a double-edged sword that enhances radiation sensitivity and facilitates radiation-induced injury in tumors","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol."},{"key":"10.1016\/j.critrevonc.2026.105292_bib59","doi-asserted-by":"crossref","DOI":"10.1002\/9781119852810","article-title":"Ferroptosis in cancer therapy: mechanisms, small molecule inducers, and novel approaches","author":"Luo","year":"2024","journal-title":"Drug Des. Dev. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105292_bib60","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41420-024-02084-2","article-title":"YTH domain family protein 3 accelerates non-small cell lung cancer immune evasion through targeting CD8(+) T lymphocytes","volume":"10","author":"Luo","year":"2024","journal-title":"Cell Death Discov."},{"issue":"9-10","key":"10.1016\/j.critrevonc.2026.105292_bib61","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s10495-024-01988-9","article-title":"The mutual regulatory role of ferroptosis and immunotherapy in anti-tumor therapy","volume":"29","author":"Mao","year":"2024","journal-title":"Apoptosis"},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105292_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/cells11193028","article-title":"Dendritic cells: the long and evolving road towards successful targetability in cancer","volume":"11","author":"Marmonti","year":"2022","journal-title":"Cells"},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105292_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14143332","article-title":"Impact and novel perspective of immune checkpoint inhibitors in patients with early and intermediate stage HCC","volume":"14","author":"Marzi","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105292_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13102495","article-title":"Recent progress in dendritic cell-based cancer immunotherapy","volume":"13","author":"Matsuo","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105292_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/cells14110812","article-title":"Dendritic cell-based cancer vaccines: the impact of modulating innate lymphoid cells on anti-tumor efficacy","volume":"14","author":"Mehrani","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105292_bib66","article-title":"Immune landscape of thyroid cancers: new insights","volume":"11","author":"Menicali","year":"2020","journal-title":"Front Endocrinol. (Lausanne)"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105292_bib67","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1172\/JCI97642","article-title":"Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance","volume":"129","author":"Muraoka","year":"2019","journal-title":"J. Clin. Invest"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105292_bib68","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/ddr.22059","article-title":"Diaryl ether derivative inhibits GPX4 expression levels to induce ferroptosis in thyroid cancer cells","volume":"84","author":"Pamarthy","year":"2023","journal-title":"Drug Dev. Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105292_bib69","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.oooo.2022.12.013","article-title":"Osteonecrosis of the jaw associated with pembrolizumab","volume":"136","author":"Pennings","year":"2023","journal-title":"Oral. Surg. Oral. Med Oral. Pathol. Oral. Radio."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105292_bib70","doi-asserted-by":"crossref","first-page":"36","DOI":"10.21037\/cco-23-133","article-title":"Immunotherapy for patients with thyroid cancer: a comprehensive appraisal","volume":"13","author":"Pinheiro Neto","year":"2024","journal-title":"Chin. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105292_bib71","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12026-025-09687-6","article-title":"Engineering CAR-T cells for solid tumors: bispecific antigen targeting, tumor microenvironment modulation, and toxicity control","volume":"73","author":"Premchandani","year":"2025","journal-title":"Immunol. Res"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105292_bib72","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1039\/D4BM00490F","article-title":"Acidity-responsive polyphenol-coordinated nanovaccines for improving tumor immunotherapy via bidirectional reshaping of the immunosuppressive microenvironment and controllable release of antigens","volume":"12","author":"Qiu","year":"2024","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.critrevonc.2026.105292_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.997873","article-title":"Construction of a ferroptosis-related eight gene signature for predicting the prognosis and immune infiltration of thyroid cancer","volume":"13","author":"Ren","year":"2022","journal-title":"Front Endocrinol. (Lausanne)"},{"key":"10.1016\/j.critrevonc.2026.105292_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1389971","article-title":"The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review","volume":"15","author":"Satapathy","year":"2024","journal-title":"Front Immunol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105292_bib75","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1001\/jamaoncol.2024.4019","article-title":"Dual immune checkpoint inhibition in patients with aggressive thyroid carcinoma: a phase 2 nonrandomized clinical trial","volume":"10","author":"Sehgal","year":"2024","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105292_bib76","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-23906-2","article-title":"Glutathione peroxidase 4 inhibition induces ferroptosis and mTOR pathway suppression in thyroid cancer","volume":"12","author":"Sekhar","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105292_bib77","article-title":"Prospects and challenges of immunotherapy for thyroid cancer","author":"Song","year":"2024","journal-title":"Endocr. Pr."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105292_bib78","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.eprac.2024.11.012","article-title":"Prospects and challenges of immunotherapy for thyroid cancer","volume":"31","author":"Song","year":"2025","journal-title":"Endocr. Pr."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105292_bib79","doi-asserted-by":"crossref","DOI":"10.3390\/cells14120936","article-title":"Spatial transcriptomics in thyroid cancer: applications, limitations, and future perspectives","volume":"14","author":"Song","year":"2025","journal-title":"Cells"},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105292_bib80","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13194821","article-title":"Secreted factors by anaplastic thyroid cancer cells induce tumor-promoting M2-like macrophage polarization through a TIM3-dependent mechanism","volume":"13","author":"Stempin","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105292_bib81","article-title":"CAR-T cell therapy in advanced thyroid cancer: from basic to clinical","volume":"15","author":"Sun","year":"2024","journal-title":"Front Immunol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105292_bib82","first-page":"7463","article-title":"Vitro ferroptotic and antitumor effect of free or liposome-encapsulated artesunate in papillary thyroid cancer cells","volume":"9","author":"Sun","year":"2024","journal-title":"ACS Omega"},{"key":"10.1016\/j.critrevonc.2026.105292_bib83","article-title":"Ferroptosis in thyroid cancer: mechanisms, current status, and treatment","volume":"15","author":"Tian","year":"2025","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2026.105292_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1369780","article-title":"Emerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy","volume":"15","author":"Turner","year":"2024","journal-title":"Front Immunol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105292_bib85","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.3390\/curroncol31070286","article-title":"Current advances in radioactive iodine-refractory differentiated thyroid cancer","volume":"31","author":"Volpe","year":"2024","journal-title":"Curr. Oncol."},{"issue":"41","key":"10.1016\/j.critrevonc.2026.105292_bib86","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202201704","article-title":"A triple therapeutic strategy with antiexosomal iron efflux for enhanced ferroptosis therapy and immunotherapy","volume":"18","author":"Wang","year":"2022","journal-title":"Small"},{"key":"10.1016\/j.critrevonc.2026.105292_bib87","article-title":"Circular RNA Circ_0067934 attenuates ferroptosis of thyroid cancer cells by miR-545-3p\/SLC7A11 signaling","author":"Wang","year":"2021","journal-title":"Front. Endocrinol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105292_bib88","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2403170","article-title":"Emerging insights into thyroid cancer from immunotherapy perspective: a bibliometric analysis","volume":"20","author":"Wang","year":"2024","journal-title":"Hum. Vaccin Immunother."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105292_bib89","doi-asserted-by":"crossref","first-page":"11149","DOI":"10.1002\/cam4.5698","article-title":"Role of tumor microenvironment in cancer progression and therapeutic strategy","volume":"12","author":"Wang","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.critrevonc.2026.105292_bib90","article-title":"A self-assembling nanoplatform for pyroptosis and ferroptosis enhanced cancer photoimmunotherapy","author":"Wang","year":"2025","journal-title":"Light Science & Applications"},{"key":"10.1016\/j.critrevonc.2026.105292_bib91","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bbrc.2021.02.126","article-title":"Vitamin C induces ferroptosis in anaplastic thyroid cancer cells by ferritinophagy activation","volume":"551","author":"Wang","year":"2021","journal-title":"Biochem Biophys. Res Commun."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105292_bib92","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1089\/dna.2021.0216","article-title":"The Knockdown of ETV4 inhibits the papillary thyroid cancer development by promoting ferroptosis upon SLC7A11 downregulation","volume":"40","author":"Wang","year":"2021","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.critrevonc.2026.105292_bib93","article-title":"Complete response of advanced cutaneous squamous cell and basal cell carcinomas with sequential cemiplimab and sonidegib therapy","author":"Weis","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105292_bib94","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1097\/JS9.0000000000001974","article-title":"Patient\u2011reported outcome measures for assessing health\u2011related quality of life in patients with differentiated thyroid cancer: a systematic review","volume":"111","author":"Xiong","year":"2025","journal-title":"Int J. Surg."},{"key":"10.1016\/j.critrevonc.2026.105292_bib95","article-title":"Ferroptosis: a novel perspective on tumor immunotherapy","volume":"16","author":"Xu","year":"2025","journal-title":"Front Immunol."},{"key":"10.1016\/j.critrevonc.2026.105292_bib96","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.1045548","article-title":"Regulation mechanism of ferroptosis and its research progress in tumor immunotherapy","volume":"9","author":"Xu","year":"2022","journal-title":"Front Mol. Biosci."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105292_bib97","article-title":"NRF2, a superstar of ferroptosis","volume":"12","author":"Yan","year":"2023","journal-title":"Antioxid. (Basel)"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105292_bib98","first-page":"464","article-title":"SIRT6 drives sensitivity to ferroptosis in anaplastic thyroid cancer through NCOA4-dependent autophagy","volume":"13","author":"Yang","year":"2023","journal-title":"Am. J. Cancer Res"},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105292_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e34291","article-title":"Shikonin inhibits the growth of anaplastic thyroid carcinoma cells by promoting ferroptosis and inhibiting glycolysis","volume":"10","author":"Yang","year":"2024","journal-title":"Heliyon"},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105292_bib100","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.18587","article-title":"The evolving process of ferroptosis in thyroid cancer: novel mechanisms and opportunities","volume":"28","author":"Yin","year":"2024","journal-title":"J. Cell Mol. Med"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105292_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellin.2024.100153","article-title":"Role of tumor cell pyroptosis in anti-tumor immunotherapy","volume":"3","author":"Zhang","year":"2024","journal-title":"Cell Insight"},{"key":"10.1016\/j.critrevonc.2026.105292_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2024.156758","article-title":"Optimizing CAR-T cell culture: differential effects of IL-2, IL-12, and IL-21 on CAR-T cells","volume":"184","author":"Zhang","year":"2024","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105292_bib103","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12943-022-01530-y","article-title":"Ferroptosis in cancer therapy: a novel approach to reversing drug resistance","volume":"21","author":"Zhang","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105292_bib104","article-title":"Ferroptosis amplifier remodels redox homeostasis for enhanced cancer chemoimmunotherapy","author":"Zhang","year":"2024","journal-title":"ACS Mater. Lett."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105292_bib105","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12943-024-02130-8","article-title":"Cuproptosis, ferroptosis and PANoptosis in tumor immune microenvironment remodeling and immunotherapy: culprits or new hope","volume":"23","author":"Zhang","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105292_bib106","article-title":"Advances in non-apoptotic regulated cell death: implications for malignant tumor treatment","volume":"15","author":"Zhang","year":"2025","journal-title":"Front Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105292_bib107","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2472496","article-title":"Emerging insights into thyroid cancer from immunotherapy perspective: a correspondence","volume":"21","author":"Zhang","year":"2025","journal-title":"Hum. Vaccin. & Immunother."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105292_bib108","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/cac2.12250","article-title":"Ferroptosis in cancer and cancer immunotherapy","volume":"42","author":"Zhao","year":"2022","journal-title":"Cancer Commun (Lond)"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105292_bib109","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/cac2.12487","article-title":"The crosstalk between ferroptosis and anti-tumor immunity in the tumor microenvironment: molecular mechanisms and therapeutic controversy","volume":"43","author":"Zheng","year":"2023","journal-title":"Cancer Commun (Lond)"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001794?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001794?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T06:42:01Z","timestamp":1778481721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826001794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":109,"alternative-id":["S1040842826001794"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105292","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy and ferroptosis regulation in thyroid cancer: Novel strategies and future perspectives","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105292","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105292"}}